What should be done about hepatitis-B-infected health-care workers? Free

Preview this article:

There is no abstract available.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.05165-0
2003-05-01
2024-03-28
Loading full text...

Full text loading...

/deliver/fulltext/jmm/52/5/JM520501.html?itemId=/content/journal/jmm/10.1099/jmm.0.05165-0&mimeType=html&fmt=ahah

References

  1. Carman W. F, Jacyna M. R, Hadziyannis S, Karayiannis P, McGarvey M. J, Makris A, Thomas H. C. 1989; Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet ii:588–591
    [Google Scholar]
  2. Department of Health 1993 Protecting health care workers and patients from hepatitis B Health Service Guidelines HSG (93) 40 London: Department of Health;
    [Google Scholar]
  3. Department of Health 1998 Guidance for clinical health care workers: protection against infection with blood-borne viruses Health Service Circular HSC (1998)/063 London: Department of Health;
    [Google Scholar]
  4. Department of Health 2000 Hepatitis B infected health care workers Health Service Circular HSC (2000)/02 London: Department of Health;
    [Google Scholar]
  5. Hadziyannis S. J, Tassopoulos N. C, Heathcote E. J. 10 other authors 2003; Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med Med 348:800–807 [CrossRef]
    [Google Scholar]
  6. Heptonstall J, Barnes J, Burton E. 25 other authors 1997; Transmission of hepatitis B from four infected surgeons without hepatitis B e antigen.The Incident Investigation Teams and others. N Engl J Med 336:178–184 [CrossRef]
    [Google Scholar]
  7. Lai C. L, Chien R. N, Leung N. W. 9 other authors 1998; A one-year trial of lamivudine for chronic hepatitis B.Asia Hepatitis Lamivudine Study Group. N Engl J Med 339:61–68 [CrossRef]
    [Google Scholar]
  8. Liaw Y.-F. 2002; Therapy of chronic hepatitis B: current challenges and opportunities. J Viral Hepat 9:393–399 [CrossRef]
    [Google Scholar]
  9. Liaw Y.-F, Leung N. W. Y, Chang T. T. 8 other authors 2000; Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B.Asia Hepatitis Lamivudine Study Group. Gastroenterology 119:172–180 [CrossRef]
    [Google Scholar]
  10. Lindh M, Horal P, Dhillon A. P, Norkrans G. 2000; Hepatitis B virus DNA levels, precore mutations, genotypes and histological activity in chronic hepatitis B. J Viral Hepat 7:258–267 [CrossRef]
    [Google Scholar]
  11. Martinot-Peignoux M, Boyer N, Colombat M. 7 other authors 2002; Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers. J Hepatol 36:543–546 [CrossRef]
    [Google Scholar]
  12. Melegari M, Scaglioni P. P, Wands J. R. 1998; Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 27:628–633 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.05165-0
Loading

Most cited Most Cited RSS feed